Impact of Policies and Performance Measurement on Development of Organizational Coordinating Strategies for Chronic Care DeliveryByLeonard Pogach, MD, MBA,Martin P. Charns, MBA, DBA,James S. Wrobel, DPM, MS,Jeffrey M. Robbins, DPM,Kristin M. Bonacker, BA,Linda Haas, PhC, RN, CDE,Gayle E. Reiber, MPH, PhDFebruary 1st 2004
High Rates of Co-occurrence of Hypertension, Elevated Low-Density Lipoprotein Cholesterol, and Diabetes Mellitus in a Large Managed Care PopulationByJoe V. Selby, MD, MPH,Tiffany Peng, MS,Andrew J. Karter, PhD,Mark Alexander, PhD,Stephen Sidney, MD, MPH,Jean Lian, PhD,Amy Arnold, MS,Dan Pettitt, DVM, MSFebruary 1st 2004
Addressing the Needs of Patients With Multiple Chronic IllnessesByJohn D. Piette, PhD,Caroline Richardson, MD,Marcia Valenstein, MD, MSFebruary 1st 2004
Costs and Utilization Associated With Pharmaceutical Adherence in a Diabetic PopulationByKera L. Hepke, MS,Mary T. Martus, RN, BSN,David A. Share, MD, MPHFebruary 1st 2004
Referral Management and the Care of Patients With DiabetesByCatherine Kim, MD, MPH,David F. Williamson, PhD,William H. Herman, MD, MPH,Monika M. Safford, MD,Joseph V. Selby, MD, MPH,David G. Marrero, PhD,J. David Curb, MD, MPH,Theodore J. Thompson, MSFebruary 1st 2004
Cholesterol Management of Patients With Diabetes in a Primary Care Practice–Based Research NetworkByDawn Fuke, PharmD,Jacquelyn Hunt, PharmD, BCPS,Joseph Siemienczuk, MD,Michael Estoup, PharmD,Michael Carroll, MD,Nicola Payne, Mphil,Daniel Touchette, PharmD, MAFebruary 1st 2004
The Intensification of Drug Therapy for Diabetes and Its ComplicationsByDavid P. Nau, RPh, PhD,Mathew C. Garber, PharmD, MA,William H. Herman, MD, MPHFebruary 1st 2004
Evaluation of Angiotensin-Converting Enzyme Inhibitor Use in Patients With Type 2 Diabetes in a State Managed Care PlanByErin M. Timpe, PharmD,Naseem Amarshi, PharmD,Pamala J. Reed, DrPHFebruary 1st 2004
Improving Diabetes Treatment Quality in Managed Care OrganizationsByMichele Heisler, MD, MPA,Edward H. Wagner, MDFebruary 1st 2004
